Information ADVERTISEMENT
About the TargetTau-1 study Study purpose The purpose of this study is to learn more about an investigational drug called BMS-986446 to see if it could be used safely and effectively to treat mild cognitive impairment due to Alzheimer’s disease, or mild Alzheimer’s dementia. It will also test its effects on memory, thinking, and daily functioning. To learn more about this Alzheimer’s disease clinical
Are you or someone you know showing early symptoms of memory loss (mild cognitive impairment) or early Alzheimer’s disease? Common early symptoms include: • Loss of memory that affects daily living • Poor judgement that leads to bad decision making • Difficulty completing familiar tasks • Repeating questions or forgetting recently learned information • Losing track of dates or locations; losing things and having trouble retracing steps • Trouble understanding visual images, resulting in difficulty reading or driving • Changes in mood and personality None of these are enough by themselves to make a diagnosis, but experiencing several of them could be cause for your doctor to investigate further. If you or someone you know are experiencing any of these symptoms, ask your doctor about Alzheimer’s disease and the TargetTau-1 study testing a new, investigational medicine for mild cognitive impairment or early Alzheimer’s disease.
study please contact: Tiffany Fitzgerald
Clinical Research Coordinator Banner Alzheimer’s Institute Phone: (520) 694-4413 Study Number: CN008-0003 Protocol v1.0_11Dec2023 CN008-0003_ADP01_AD Poster_v1.0_29Mar2024_US English ©2024 Bristol-Myers Squibb Company
Page 14 | March & April 2025, Never Too Late
Pima Council on Aging
Made with FlippingBook - Share PDF online